Argent BioPharma halves losses but faces funding ‘uncertainty’ by Adam Sheldon September 1, 2026September 1, 2026 Clinical biotech Argent BioPharma cut its annual loss by 57% to $7.7 million in FY26 as […]
Argent shares soar after CannEpil deal wipes out US$5.5m debt by Adam Sheldon July 7, 2026July 7, 2026
